Samsung Bioepis' Keytruda Biosimilar: Real Patient Outcomes and Market Comparison
Samsung Bioepis Proves Clinical Equivalence of Keytruda Biosimilar
South Korea’s Samsung Bioepis has confirmed clinical equivalence for its Keytruda biosimilar (SB16) in Phase 3 trials, securing a leading position in the upcoming market competition. This marks an early sign of intense rivalry in the global immunotherapy drug sector.
Market Competition Heats Up in $43 Billion Sector
With Keytruda’s patent set to expire, a $43 trillion biosimilar market is opening up, intensifying competition between Samsung Bioepis and Celltrion. This has become one of the most closely watched cases in South Korea’s biopharmaceutical industry.
Samsung Bioepis began global Phase 3 clinical trials in April 2024, with domestic regulatory submissions expected by August 2026. The company successfully launched its biosimilar in Japan and plans to present real-world prescription data for 'Adalchera' at KCR 2026.
Keytruda Biosimilar Market Size and Competitive Landscape
The Keytruda biosimilar market is projected to reach approximately $44 billion, with Samsung Bioepis and Celltrion leading the competition. The market opening following Keytruda’s patent expiration is expected to bring significant changes to the global pharmaceutical sector.
Having completed Phase 3 trials for SB16 and confirmed clinical equivalence, Samsung Bioepis has laid a strong foundation for its market entry. Celltrion, however, has already launched its Keytruda biosimilar, putting Samsung Bioepis in a追赶 position.
The successful launch of the biosimilar in Japan provided Samsung Bioepis with a strategic advantage. This achievement has served as an important stepping stone for global market expansion.
Keytruda’s patent expiration is anticipated around 2026, and competition in this sector will likely intensify. Samsung Bioepis plans to present real-world prescription data at KCR 2026 to strengthen its market position.
Clinical Equivalence Confirmation and Future Outlook
By confirming clinical equivalence for SB16 in Phase 3 trials, Samsung Bioepis has set the stage for intensified competition in the immunotherapy drug market. The company’s lead in Keytruda biosimilar development is now confirmed.
Clinical results are expected to be finalized by 2026, with data to be presented at KCR 2026. SB16 is anticipated to become a competitive product following Keytruda’s patent expiration.
After initiating global Phase 3 trials, Samsung Bioepis is preparing for domestic regulatory submissions, further highlighting the growing rivalry with Celltrion.
The Keytruda biosimilar market is projected at $48 billion, with fierce competition between Samsung Bioepis and Celltron. This will be a critical opportunity for South Korea’s biopharmaceutical industry to strengthen its global competitiveness.
Having successfully launched the first biosimilar in Japan, Samsung Bioepis has gained strategic momentum for global market expansion. Future growth is expected both through increased exports and enhanced domestic competitiveness.

Market Shifts Following Patent Expiry
The $43 billion competition triggered by Keytruda’s patent expiry has already begun. Samsung Bioepis has confirmed clinical equivalence for SB16 and is advancing regulatory submissions.
Celltrion has already launched its Keytruda biosimilar, placing Samsung Bioepis in a position to catch up. Japan’s market success has become a key strategic factor for Samsung Bioepis.
From August 2024 onwards, media coverage of Keytruda biosimilar developments has intensified, making the competitive landscape between Samsung Bioepis and Celltrion more distinct. This case is being closely monitored as an important example of South Korean companies building global competitiveness.
Market Outlook and Strategic Responses
The Keytruda biosimilar market is projected at $48 billion, reflecting large-scale changes in the pharmaceutical sector following blockbuster drug patent expirations. Samsung Bioepis and Celltrion are each developing strategies to compete in this space.
Based on SB16 Phase 3 trial results, Samsung Bioepis is preparing for market entry. Data will be presented at KCR 2026 to strengthen its position in the market.
Celltrion has already launched its Keytruda biosimilar, and while its market share expansion is expected, Samsung Bioepis has established a foundation for global market entry through success in Japan.
Key Information
Samsung Bioepis announced clinical equivalence confirmation for SB16 on August 31, 2024, marking a signal that it is outpacing competitor Celltrion. Keytruda’s patent expiration is expected around 2026, with the market size estimated at approximately $48 billion.
Having successfully launched its first biosimilar in Japan, Samsung Bioepis has gained strategic success for global market expansion. Real-world prescription data for 'Adalchera' will be presented at KCR 2026 in May.
Frequently Asked Questions
What clinical results did Samsung Bioepis confirm for its Keytruda biosimilar?
Samsung Bioepis confirmed clinical equivalence in Phase 3 trials for SB16. This has marked the beginning of intensified competition in the immunotherapy drug market.
How large is the Keytruda biosimilar market?
The Keytruda biosimilar market is projected to reach approximately $48 billion, reflecting significant changes following patent expiration of a blockbuster pharmaceutical product.
What is the competitive landscape between Samsung Bioepis and Celltrion?
Samsung Bioepis has completed Phase 3 trials for SB16 and confirmed clinical equivalence, positioning itself to catch up with Celltrion. Samsung’s success in Japan has provided a strategic foundation for global market entry.
Frequently Asked Questions
With its Keytruda biosimilar (SB16) demonstrating clinical equivalence in Phase 3 trials, Samsung Bioepis is securing a leading position in the global immunotherapy drug market. This marks an important turning point for South Korea’s biopharmaceutical industry to build competitiveness on the world stage.
The $43 billion competition driven by Keytruda’s patent expiration has intensified rivalry between Samsung Bioepis and Celltrion. Through its success in Japan and planned presentation of real-world prescription data at KCR 2026, Samsung Bioepis aims to expand market share.
Competition in the Keytruda biosimilar sector is expected to become clearer within the next year, with Samsung Bioepis advancing strategic initiatives to strengthen its global competitiveness.
Samsung Bioepis’ development of a Keytruda biosimilar represents an important case for South Korean companies building global pharmaceutical market presence. This will continue to draw significant attention in the coming years.
Explore more articles on similar topics.
View Related ArticlesFAQ
What clinical results did Samsung Bioepis confirm for its Keytruda biosimilar?
Samsung Bioepis confirmed clinical equivalence in Phase 3 trials for SB16. This has marked the beginning of intensified competition in the immunotherapy drug market.
How large is the Keytruda biosimilar market?
The Keytruda biosimilar market is projected to reach approximately $48 billion, reflecting significant changes following patent expiration of a blockbuster pharmaceutical product.
What is the competitive landscape between Samsung Bioepis and Celltrion?
Samsung Bioepis has completed Phase 3 trials for SB16 and confirmed clinical equivalence, positioning itself to catch up with Celltrion. Samsung’s success in Japan has provided a strategic foundation for global market entry.
Korean Source
This article is an English localization of a Korean-language report from BlogScore. Original: 삼성바이오에피스 키트루다 효과: 실제 환자 사례와 비교